These findings suggest that ERp29 may stimulate the inactivation of ERK1/2 and AKT, contributing to inhibit EMT process and then reduce the tumorigenicity of human gastric cancer cells (Figure 6D). This evidence concerns the gene ERP29 and gastric cancer.